Colonic mucosal associated invariant T cells in Crohn's disease have a diverse and non-public T cell receptor beta chain repertoire.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 03 05 2023
accepted: 13 10 2023
medline: 6 11 2023
pubmed: 3 11 2023
entrez: 3 11 2023
Statut: epublish

Résumé

Mucosal-Associated Invariant T (MAIT) cells are T cells with a semi-invariant T cell receptor (TCR), recognizing riboflavin precursors presented by a non-polymorphic MR1 molecule. As these precursors are produced by the gut microbiome, we characterized the frequency, phenotype and clonality of MAIT cells in human colons with and without Crohn's disease (CD). The transcriptome of MAIT cells sorted from blood and intestinal lamina propria cells from colectomy recipients were compared with other CD8+ T cells. Colon biopsies from an additional ten CD patients and ten healthy controls (HC) were analyzed by flow cytometry. TCR genes were sequenced from individual MAIT cells from these biopsies and compared with those of MAIT cells from autologous blood. MAIT cells in the blood and colon showed a transcriptome distinct from other CD8 T cells, with more expression of the IL-23 receptor. MAIT cells were enriched in the colons of CD patients, with less NKG2D in inflamed versus uninflamed segments. Regardless of disease, most MAIT cells expressed integrin α4β7 in the colon but not in the blood, where they were enriched for α4β7 expression. TCR sequencing revealed heterogeneity in the colon and blood, with few public sequences associated with cohorts. MAIT cells are enriched in the colons of CD patients and disproportionately express molecules (IL-23R, integrin α4β7) targeted by CD therapeutics, to suggest a pathogenic role for them in CD. Public TCR sequences were neither common nor sufficiently restricted to a cohort to suggest protective or pathogenic antigen-specificities.

Identifiants

pubmed: 37922286
doi: 10.1371/journal.pone.0285918
pii: PONE-D-23-11399
pmc: PMC10624325
doi:

Substances chimiques

Receptors, Antigen, T-Cell, alpha-beta 0
Histocompatibility Antigens Class I 0
Receptors, Antigen, T-Cell 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0285918

Informations de copyright

Copyright: © 2023 Konecny et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Immunol. 2015 Jun 15;194(12):5775-80
pubmed: 25980010
Nat Immunol. 2007 Sep;8(9):967-74
pubmed: 17581537
Gastroenterology. 2017 Jul;153(1):77-86.e6
pubmed: 28390867
Int Immunol. 2011 Sep;23(9):529-35
pubmed: 21712423
Intensive Care Med. 2014 Feb;40(2):192-201
pubmed: 24322275
Clin Immunol. 2016 May;166-167:1-11
pubmed: 27050759
J Clin Invest. 2015 Apr;125(4):1752-62
pubmed: 25751065
Eur J Immunol. 2016 Sep;46(9):2204-10
pubmed: 27296288
Methods Mol Biol. 2015;1343:181-97
pubmed: 26420718
Gastroenterology. 2017 Nov;153(5):1392-1403.e2
pubmed: 28780074
ISRN Inflamm. 2014 Mar 25;2014:928461
pubmed: 25101191
Biomed Res. 2017;38(2):111-121
pubmed: 28442662
Inflamm Bowel Dis. 2019 Aug 20;25(9):1497-1509
pubmed: 30918941
Nature. 2012 Nov 1;491(7422):119-24
pubmed: 23128233
World J Gastroenterol. 2017 May 14;23(18):3240-3251
pubmed: 28566883
J Immunol. 2013 Apr 1;190(7):3142-52
pubmed: 23447689
PLoS One. 2013 Oct 04;8(10):e76008
pubmed: 24124528
Inflamm Bowel Dis. 2015 Jan;21(1):19-30
pubmed: 25437819
Clin Exp Immunol. 2020 Feb;199(2):201-215
pubmed: 31587268
Scand J Immunol. 2016 Oct;84(4):245-51
pubmed: 27474379
J Exp Med. 1993 Jul 1;178(1):1-16
pubmed: 8391057
Brain. 2013 Sep;136(Pt 9):2888-903
pubmed: 23864273
Nat Commun. 2014;5:3143
pubmed: 24452018
Sci Immunol. 2019 Nov 15;4(41):
pubmed: 31732518
J Rheumatol Suppl. 2005 Mar;74:35-9
pubmed: 15742463
Br J Dermatol. 2017 Jul;177(1):267-270
pubmed: 27599204
J Immunol. 2012 Jun 1;188(11):5438-47
pubmed: 22539793
Hum Pathol. 1975 Jan;6(1):7-29
pubmed: 1089084
J Exp Med. 2013 Oct 21;210(11):2305-20
pubmed: 24101382
Nature. 1994 Nov 10;372(6502):190-3
pubmed: 7969453
Immunity. 2018 Jan 16;48(1):161-173.e5
pubmed: 29305140
Eur J Immunol. 2016 Oct;46(10):2444-2453
pubmed: 27461134
Proc Natl Acad Sci U S A. 2009 May 19;106(20):8290-5
pubmed: 19416870
Eur J Immunol. 2014 Oct;44(10):3119-28
pubmed: 25043505
Immunol Cell Biol. 2018 May;96(5):507-525
pubmed: 29437263
PLoS One. 2012;7(12):e51819
pubmed: 23251632
Front Immunol. 2017 Apr 06;8:398
pubmed: 28428786
Inflamm Bowel Dis. 2007 May;13(5):511-5
pubmed: 17309073
Lancet. 2008 May 17;371(9625):1675-84
pubmed: 18486740
J Immunol. 2018 Mar 1;200(5):1901-1916
pubmed: 29378910
J Exp Med. 1999 Jun 21;189(12):1907-21
pubmed: 10377186
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3006-11
pubmed: 20133607
Brain. 2011 Feb;134(Pt 2):542-54
pubmed: 21216829
Blood. 2013 Feb 14;121(7):1124-35
pubmed: 23243281
Lancet. 2008 May 17;371(9625):1665-74
pubmed: 18486739
Gut. 1990 May;31(5):536-8
pubmed: 2190866
Inflamm Bowel Dis. 2015 Jul;21(7):1529-40
pubmed: 25946569
Nat Immunol. 2016 Nov;17(11):1300-1311
pubmed: 27668799
Eur J Immunol. 2015 Aug;45(8):2286-98
pubmed: 26046663
Science. 2023 Sep 15;381(6663):eadh0301
pubmed: 37708268
Nature. 2012 Nov 29;491(7426):717-23
pubmed: 23051753
Semin Immunol. 2007 Dec;19(6):372-6
pubmed: 18319054
Inflamm Bowel Dis. 2017 Sep;23(9):1524-1534
pubmed: 28700533
BioDrugs. 2020 Dec;34(6):713-721
pubmed: 33105016
Eur J Immunol. 2014 Jan;44(1):195-203
pubmed: 24019201
Front Immunol. 2017 Oct 11;8:1252
pubmed: 29075255
Nat Commun. 2014 May 15;5:3866
pubmed: 24832684
Nature. 2003 Mar 13;422(6928):164-9
pubmed: 12634786
Gut. 2017 Nov;66(11):1918-1925
pubmed: 27489241
J Gastroenterol Hepatol. 2016 May;31(5):965-72
pubmed: 26590105
N Engl J Med. 2012 Oct 18;367(16):1519-28
pubmed: 23075178
Gut. 2004 Aug;53(8):1117-22
pubmed: 15247177
PLoS Biol. 2010 Jun 29;8(6):e1000407
pubmed: 20613858
PLoS One. 2016 Aug 25;11(8):e0161786
pubmed: 27560150
PLoS One. 2014 Aug 20;9(8):e105375
pubmed: 25141347
Front Med. 2015 Mar;9(1):10-9
pubmed: 25652649
Dig Dis Sci. 2021 Feb;66(2):348-358
pubmed: 33089484
PLoS Pathog. 2015 Aug 21;11(8):e1005072
pubmed: 26295709
Gastroenterology. 2006 May;130(6):1764-75
pubmed: 16697740
Eur J Immunol. 2017 Nov;47(11):2002-2003
pubmed: 28815578
Am J Pathol. 2012 Jul;181(1):8-18
pubmed: 22640807
J Exp Med. 2014 Jul 28;211(8):1601-10
pubmed: 25049333
Clin Cancer Res. 2014 Apr 15;20(8):2215-25
pubmed: 24573552
Science. 2006 Dec 1;314(5804):1461-3
pubmed: 17068223
Cytokine Growth Factor Rev. 2010 Oct;21(5):365-79
pubmed: 20870448
Semin Immunopathol. 2019 May;41(3):283-297
pubmed: 30891627
Lancet. 2017 Apr 29;389(10080):1699-1709
pubmed: 28411872
J Immunol. 2017 Jul 1;199(1):107-118
pubmed: 28576979
Arthritis Rheum. 2012 Jan;64(1):153-61
pubmed: 21904999
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
Gut. 2009 Aug;58(8):1152-67
pubmed: 19592695
Clin Exp Immunol. 2014 May;176(2):266-74
pubmed: 24450998
Blood. 2011 Jan 27;117(4):1250-9
pubmed: 21084709

Auteurs

Andrew J Konecny (AJ)

Benaroya Research Institute, Translational Research Program, Seattle, WA, United States of America.
Department of Immunology, University of Washington, Seattle, WA, United States of America.

Donna M Shows (DM)

Benaroya Research Institute, Translational Research Program, Seattle, WA, United States of America.

James D Lord (JD)

Benaroya Research Institute, Translational Research Program, Seattle, WA, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH